RANI - Rani Therapeutics' hormone drug RT-102 for osteoporosis well-tolerated in phase 1 study

• Rani Therapeutics ( NASDAQ: RANI ) on Wednesday said its capsule RT-102 for the potential treatment of osteoporosis was generally well-tolerated in a phase 1 study.
• The single-ascending dose portion of the early-stage study, called Study Part 1, met all its main goals, RANI said.
• The endpoints of the study, which was conducted in Australia in 39 healthy adult female volunteers, were safety and tolerability, and measurements of serum concentrations of RT-102.
• "We plan on sharing these results with the (U.S. FDA) and, subject to a successful IND filing, initiating a Phase 2 trial for RT-102 in the U.S. in 3Q 2023," said RANI CEO Talat Imran.
• RANI separately announced a class A common stock offering and reported Q2 results .
• Rani ( RANI ) stock was down 3.2% to $10.75 after hours.

For further details see: